Immunotherapy Keytruda for Early-Stage Triple-Negative Breast Cancer: Better pCR and Lower Recurrence Rates: ESMO 2019 Coverage

Breastcancer.org Podcast

Content provided by Caroline Durham. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Caroline Durham or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

3y ago 9:27

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on April 01, 2022 06:22 (2y ago). Last successful fetch was on February 28, 2022 07:18 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Dr. Peter Schmid is chair in cancer medicine at Barts Cancer Institute, Queen Mary University London and also serves as clinical director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and honorary consultant medical oncologist at Barts Hospital. His research focuses on breast cancer, cancer immune therapy, and early drug development. At the European Society for Medical Oncology 2019 Congress, he presented results from the KEYNOTE-522 study showing that the combination of the immunotherapy Keytruda (chemical name: pembrolizumab) and chemotherapy before surgery to remove early-stage triple-negative breast cancer led to a better pathologic complete response than chemotherapy alone. This is the first phase III study using immunotherapy to treat early-stage breast cancer. Listen to the podcast to hear Dr. Schmid discuss: the design of the KEYNOTE-522 study side effects related to both chemotherapy and Keytruda what these results mean for patients Running time: 9:27

215 episodes

#Science #Medicine #Breast Cancer #Caroline Durham #Health and Well-Being #Podcasting Education